BPMC News and Press, Blueprint Medicines Corporation From 12/19/21

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors PR Newswire CAMBRIDGE, Mass. , Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directo...

Blueprint Medicines' (NASDAQ:BPMC) Compensation Committee board granted non-qualified stock options to purchase 39,862 shares and 19,930 restricted stock units (RSU) to 13 new employees under Blueprint Medicines' 2020 Inducement Plan. The options have an exercise price of $96.03/share; e...

Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis -- Blueprint Medicines to present additional data underscoring commitment to transform SM care at 63rd ASH An...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Blueprint Medicines Corporation (NASDAQ:BPMC) announced a definitive agreement to acquire Lengo Therapeutics, a closely held precision oncology company for a total consideration of more than $400M. For the acquisition, the company is set to pay $250M in cash and up to $215M in additional paym...

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics -- Adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint Medicines' lung cancer pipeline -- ...

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November

Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands g...

-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BL...